# DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

> **NCT03059485** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 82 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **BIOLOGICAL:** DC/AML Fusion Vaccine
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT03059485
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-01
- **Primary completion:** 2026-09-04
- **Final completion:** 2026-12-04
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059485, "DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03059485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*